Cantor Fitzgerald Estimates 89bio FY2026 Earnings

89bio, Inc. (NASDAQ:ETNB - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of 89bio in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will post earnings of ($2.87) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for 89bio's current full-year earnings is ($3.19) per share.

89bio (NASDAQ:ETNB - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.01. During the same quarter last year, the firm earned ($0.54) earnings per share.

A number of other equities analysts have also recently weighed in on ETNB. HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target (down from $29.00) on shares of 89bio in a research note on Friday, February 28th. Citigroup assumed coverage on shares of 89bio in a research note on Thursday, March 13th. They set a "buy" rating and a $25.00 price target on the stock. The Goldman Sachs Group assumed coverage on shares of 89bio in a research note on Friday, March 14th. They set a "neutral" rating and a $11.00 price target on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of 89bio in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $26.43.

89bio Price Performance

Shares of NASDAQ:ETNB traded up $0.79 on Wednesday, reaching $10.41. 3,933,699 shares of the company were exchanged, compared to its average volume of 1,499,119. The company has a current ratio of 11.66, a quick ratio of 11.66 and a debt-to-equity ratio of 0.09. 89bio has a 1-year low of $4.16 and a 1-year high of $11.84. The firm has a market cap of $1.52 billion, a price-to-earnings ratio of -3.58 and a beta of 1.30. The company has a 50-day moving average of $8.06 and a 200-day moving average of $8.27.

Insider Buying and Selling

In related news, insider Quoc Le-Nguyen sold 15,329 shares of the business's stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $5.95, for a total value of $91,207.55. Following the sale, the insider now directly owns 328,323 shares in the company, valued at $1,953,521.85. The trade was a 4.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.60% of the company's stock.

Institutional Investors Weigh In On 89bio

Several institutional investors and hedge funds have recently made changes to their positions in ETNB. CWM LLC boosted its position in shares of 89bio by 9,265.1% in the 1st quarter. CWM LLC now owns 5,900 shares of the company's stock worth $43,000 after buying an additional 5,837 shares in the last quarter. Federated Hermes Inc. boosted its position in shares of 89bio by 206.9% in the 4th quarter. Federated Hermes Inc. now owns 6,283 shares of the company's stock worth $49,000 after buying an additional 4,236 shares in the last quarter. Quarry LP purchased a new stake in shares of 89bio in the 4th quarter worth about $55,000. GAMMA Investing LLC lifted its holdings in 89bio by 4,898.7% in the 1st quarter. GAMMA Investing LLC now owns 7,648 shares of the company's stock valued at $56,000 after purchasing an additional 7,495 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new position in 89bio in the 4th quarter valued at about $87,000.

About 89bio

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.